Literature DB >> 16729353

Different histopathological subtypes of Hodgkin lymphoma show significantly different levels of FDG uptake.

Martin Hutchings1, Annika Loft, Mads Hansen, Elisabeth Ralfkiaer, Lena Specht.   

Abstract

Positron emission tomography using 2-[18F]fluoro-2-deoxy-D-glucose (FDG-PET) enables quantitative analysis of metabolic activity. This study investigated standardized uptake value (SUV) levels in the different histopathological subtypes of Hodgkin lymphoma (HL). Sixty patients with newly diagnosed HL underwent staging FDG-PET/CT after lymph node biopsy. Maximum SUV in each patient (SUV(max/total)) and in each affected region or organ (SUV(max)) were recorded. Mean SUV(max/total) was 9.3 g/ml in seven nodular lymphocyte predominance (NLP) patients, 16.3 g/ml in 38 nodular sclerosis (NS) patients, 20.8 g/ml in 11 mixed cellularity (MC) patients, and 19.5 g/ml in four patients with unclassified classical HL (CHL-NOS), (ANOVA, p = 0.011). Out of 780 sites (600 lymph node regions plus 180 organs), 208 sites were found to be affected with HL. Mean SUV(max) was 8.3 g/ml in the 12 sites with NLP, 11.2 g/ml in the 147 sites affected with NS, 14.6 g/ml in the 36 sites with MC, and 13.1 g/ml in the 13 sites with CHL-NOS (ANOVA, p = 0.002). There is a significant difference in FDG/glucose uptake between the different histopathological subtypes of HL. Copyright 2006 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16729353     DOI: 10.1002/hon.782

Source DB:  PubMed          Journal:  Hematol Oncol        ISSN: 0278-0232            Impact factor:   5.271


  19 in total

1.  High maximum standard uptake value (SUVmax) on PET scan is associated with shorter survival in patients with diffuse large B cell lymphoma.

Authors:  Dai Chihara; Yasuhiro Oki; Hiroshi Onoda; Hirofumi Taji; Kazuhito Yamamoto; Tsuneo Tamaki; Yasuo Morishima
Journal:  Int J Hematol       Date:  2011-04-06       Impact factor: 2.490

2.  Concordance between four European centres of PET reporting criteria designed for use in multicentre trials in Hodgkin lymphoma.

Authors:  Sally F Barrington; Wendi Qian; Edward J Somer; Antonella Franceschetto; Bruno Bagni; Eva Brun; Helén Almquist; Annika Loft; Liselotte Højgaard; Massimo Federico; Andrea Gallamini; Paul Smith; Peter Johnson; John Radford; Michael J O'Doherty
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-05-27       Impact factor: 9.236

Review 3.  Recent advances in the diagnosis and therapy of Richter's syndrome.

Authors:  Ronan Swords; John Bruzzi; Francis Giles
Journal:  Med Oncol       Date:  2007       Impact factor: 3.064

4.  (18)F-FDG PET/CT bone/bone marrow findings in Hodgkin's lymphoma may circumvent the use of bone marrow trephine biopsy at diagnosis staging.

Authors:  Gerard Moulin-Romsee; Elif Hindié; Xavier Cuenca; Pauline Brice; Didier Decaudin; Myriam Bénamor; Josette Brière; Marcela Anitei; Jean-Emmanuel Filmont; David Sibon; Eric de Kerviler; Jean-Luc Moretti
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-03-04       Impact factor: 9.236

Review 5.  FDG PET/CT in children and adolescents with lymphoma.

Authors:  Regine Kluge; Lars Kurch; Françoise Montravers; Christine Mauz-Körholz
Journal:  Pediatr Radiol       Date:  2013-03-24

6.  Prognostic value of metabolic tumour volume on baseline 18F-FDG PET/CT in addition to NCCN-IPI in patients with diffuse large B-cell lymphoma: further stratification of the group with a high-risk NCCN-IPI.

Authors:  Qaid Ahmed Shagera; Gi Jeong Cheon; Youngil Koh; Min Young Yoo; Keon Wook Kang; Dong Soo Lee; E Edmund Kim; Sung-Soo Yoon; June-Key Chung
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-04-02       Impact factor: 9.236

7.  Kikuchi-Fujimoto disease mimicking malignant lymphoma with 2-[(18)F]fluoro-2-deoxy-D-glucose PET/CT in children.

Authors:  Ji Eun Kim; Eun Kyung Lee; Jae Min Lee; Soon Hwan Bae; Kwang Hae Choi; Young Hwan Lee; Jeong Ok Hah; Joon Hyuk Choi; Eun Jung Kong; Ihn Ho Cho
Journal:  Korean J Pediatr       Date:  2014-05-31

8.  Performance of FDG PET/CT at initial diagnosis in a rare lymphoma: nodular lymphocyte-predominant Hodgkin lymphoma.

Authors:  Jean François Grellier; Laetitia Vercellino; Thierry Leblanc; Pascal Merlet; Catherine Thieblemont; Pierre Weinmann; Marie-Elisabeth Toubert; Nathalie Berenger; Josette Brière; Pauline Brice
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-06-26       Impact factor: 9.236

9.  [18F]EF3 is not superior to [18F]FMISO for PET-based hypoxia evaluation as measured in a rat rhabdomyosarcoma tumour model.

Authors:  Ludwig Dubois; Willy Landuyt; Lieselotte Cloetens; Anne Bol; Guy Bormans; Karin Haustermans; Daniel Labar; Johan Nuyts; Vincent Grégoire; Luc Mortelmans
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-08-09       Impact factor: 9.236

10.  Nodular lymphocyte predominant Hodgkin lymphoma (NLPHL)-clinicopathological features based on the data of two Hungarian lymphoma centres.

Authors:  A Illés; Zs Simon; E Tóth; A Rosta; Zs Miltényi; Zs Molnár
Journal:  Pathol Oncol Res       Date:  2008-04-23       Impact factor: 3.201

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.